Cargando…
Multicentric Study to Assess Helicobacter pylori Incidence, Patient Reported Adverse Events, Compliance and Effectiveness, in Real-World Setting
Helicobacter pylori ( H. pylori) plays an important role in chronic gastritis and globally it is estimated to be present in half of the world’s population. In Portugal, prevalence reaches 85% and its eradication is recommended using quadruple antibiotic therapy, with or without bismuth. We intended...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9566079/ https://www.ncbi.nlm.nih.gov/pubmed/36232149 http://dx.doi.org/10.3390/ijerph191912847 |
_version_ | 1784809053623418880 |
---|---|
author | Mesquita, André Rocha-Castro, Carlos Guimarães, Daniela Costa, Joana Soutinho, Joana Taveira-Gomes, Tiago |
author_facet | Mesquita, André Rocha-Castro, Carlos Guimarães, Daniela Costa, Joana Soutinho, Joana Taveira-Gomes, Tiago |
author_sort | Mesquita, André |
collection | PubMed |
description | Helicobacter pylori ( H. pylori) plays an important role in chronic gastritis and globally it is estimated to be present in half of the world’s population. In Portugal, prevalence reaches 85% and its eradication is recommended using quadruple antibiotic therapy, with or without bismuth. We intended to characterize the prescribed treatments evaluating effectiveness, adverse outcomes and compliance in a real-world setting in a primary care unit. A prospective multicenter observational cohort study was developed in five primary care units of Braga, Portugal. Patients diagnosed with H. pylori infection from August 2021 to January 2022 were included. Data were collected by interview (3 weeks after treatment) and review of medical records. Comparison between two groups of treatment and multivariable analysis was conducted. We estimated 13.4 cases per 1000 adults/year from 185 diagnoses. Therapy with bismuth was the most prescribed (83.8%) with a 96.7% eradication rate. There were no significant differences between treatments. Adverse events were reported in 73.8% of inquiries and female patients were associated with higher reports of nausea (p = 0.03) and metallic taste (p = 0.02). Both eradication schemes were effective and secure. The higher rate of adverse outcomes should be validated but it could influence the debate concerning treating all patients, especially in low gastric cancer-prevalence regions. |
format | Online Article Text |
id | pubmed-9566079 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-95660792022-10-15 Multicentric Study to Assess Helicobacter pylori Incidence, Patient Reported Adverse Events, Compliance and Effectiveness, in Real-World Setting Mesquita, André Rocha-Castro, Carlos Guimarães, Daniela Costa, Joana Soutinho, Joana Taveira-Gomes, Tiago Int J Environ Res Public Health Article Helicobacter pylori ( H. pylori) plays an important role in chronic gastritis and globally it is estimated to be present in half of the world’s population. In Portugal, prevalence reaches 85% and its eradication is recommended using quadruple antibiotic therapy, with or without bismuth. We intended to characterize the prescribed treatments evaluating effectiveness, adverse outcomes and compliance in a real-world setting in a primary care unit. A prospective multicenter observational cohort study was developed in five primary care units of Braga, Portugal. Patients diagnosed with H. pylori infection from August 2021 to January 2022 were included. Data were collected by interview (3 weeks after treatment) and review of medical records. Comparison between two groups of treatment and multivariable analysis was conducted. We estimated 13.4 cases per 1000 adults/year from 185 diagnoses. Therapy with bismuth was the most prescribed (83.8%) with a 96.7% eradication rate. There were no significant differences between treatments. Adverse events were reported in 73.8% of inquiries and female patients were associated with higher reports of nausea (p = 0.03) and metallic taste (p = 0.02). Both eradication schemes were effective and secure. The higher rate of adverse outcomes should be validated but it could influence the debate concerning treating all patients, especially in low gastric cancer-prevalence regions. MDPI 2022-10-07 /pmc/articles/PMC9566079/ /pubmed/36232149 http://dx.doi.org/10.3390/ijerph191912847 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Mesquita, André Rocha-Castro, Carlos Guimarães, Daniela Costa, Joana Soutinho, Joana Taveira-Gomes, Tiago Multicentric Study to Assess Helicobacter pylori Incidence, Patient Reported Adverse Events, Compliance and Effectiveness, in Real-World Setting |
title | Multicentric Study to Assess Helicobacter pylori Incidence, Patient Reported Adverse Events, Compliance and Effectiveness, in Real-World Setting |
title_full | Multicentric Study to Assess Helicobacter pylori Incidence, Patient Reported Adverse Events, Compliance and Effectiveness, in Real-World Setting |
title_fullStr | Multicentric Study to Assess Helicobacter pylori Incidence, Patient Reported Adverse Events, Compliance and Effectiveness, in Real-World Setting |
title_full_unstemmed | Multicentric Study to Assess Helicobacter pylori Incidence, Patient Reported Adverse Events, Compliance and Effectiveness, in Real-World Setting |
title_short | Multicentric Study to Assess Helicobacter pylori Incidence, Patient Reported Adverse Events, Compliance and Effectiveness, in Real-World Setting |
title_sort | multicentric study to assess helicobacter pylori incidence, patient reported adverse events, compliance and effectiveness, in real-world setting |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9566079/ https://www.ncbi.nlm.nih.gov/pubmed/36232149 http://dx.doi.org/10.3390/ijerph191912847 |
work_keys_str_mv | AT mesquitaandre multicentricstudytoassesshelicobacterpyloriincidencepatientreportedadverseeventscomplianceandeffectivenessinrealworldsetting AT rochacastrocarlos multicentricstudytoassesshelicobacterpyloriincidencepatientreportedadverseeventscomplianceandeffectivenessinrealworldsetting AT guimaraesdaniela multicentricstudytoassesshelicobacterpyloriincidencepatientreportedadverseeventscomplianceandeffectivenessinrealworldsetting AT costajoana multicentricstudytoassesshelicobacterpyloriincidencepatientreportedadverseeventscomplianceandeffectivenessinrealworldsetting AT soutinhojoana multicentricstudytoassesshelicobacterpyloriincidencepatientreportedadverseeventscomplianceandeffectivenessinrealworldsetting AT taveiragomestiago multicentricstudytoassesshelicobacterpyloriincidencepatientreportedadverseeventscomplianceandeffectivenessinrealworldsetting |